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Effective treatment for chronic infections is undermined by a signif-
icant gap in understanding of the physiological state of pathogens
at the site of infection. Chronic pulmonary infections are responsible
for the morbidity and mortality of millions of immunocompromised
individuals worldwide, yet drugs that are successful in laboratory
culture are far less effective against pathogen populations persist-
ing in vivo. Laboratory models, upon which preclinical development
of new drugs is based, can only replicate host conditions when we
understand the metabolic state of the pathogens and the degree of
heterogeneity within the population. In this study, we measured
the anabolic activity of the pathogen Staphylococcus aureus directly
in the sputum of pediatric patients with cystic fibrosis (CF), by com-
bining the high sensitivity of isotope ratio mass spectrometry with a
heavy water labeling approach to capture the full range of in situ
growth rates. Our results reveal S. aureus generation times with a
median of 2.1 d, with extensive growth rate heterogeneity at the
single-cell level. These growth rates are far below the detection limit
of previous estimates of CF pathogen growth rates, and the rates
are slowest in acutely sick patients undergoing pulmonary exacer-
bations; nevertheless, they are accessible to experimental replica-
tion within laboratory models. Treatment regimens that include
specific antibiotics (vancomycin, piperacillin/tazobactam, tobramy-
cin) further appear to correlate with slow growth of S. aureus on
average, but follow-up longitudinal studies must be performed to
determine whether this effect holds for individual patients.
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hydrogen isotope labeling
Growth rate is arguably the simplest yet most profound phe-notypic parameter that defines microbial existence. It inte-
grates multiple aspects of a cell’s physiological state, and is often
correlated with how cells respond to challenges presented by
diverse stressors, including the immune system and antimicrobial
drugs (1–4). Despite recognition that growth rate impacts mi-
crobial persistence, very few direct measurements of in vivo gen-
eration times exist, in large part because quantifying this parameter
within a complex environment presents considerable technical
challenges. Chronic infections are often assumed to comprise
dormant pathogens, but whether they are truly dormant or merely
growing slowly is unknown.
In this study, we focused our attention on the microbial pop-
ulations within the lungs of patients with cystic fibrosis (CF). CF
patients expectorate infected mucus daily, making the in vivo
environment directly accessible to experimental investigation. Few
prior estimates of microbial growth rates exist for CF sputum
(5–7). These estimates are based on detecting the ribosomal RNA
(rRNA) content of bacterial cells using fluorescence in situ hy-
bridization (FISH). Kragh et al. (6), for example, showed that the
majority of Pseudomonas aeruginosa cells in explanted CF lung
samples display similar amounts of rRNA to cells in stationary
phase, with an rRNA content below that detected for cells in the
slowest exponentially growing batch cultures (∼0.35 divisions per
hour). Although fluorescence intensity can assess growth when the
cellular generation time is faster than ∼3 h, use of rRNA abun-
dance as a quantitative proxy for slow growth in dynamically
changing environments is limited because rRNA content can be-
come completely decoupled from growth (8). This fundamental
biological constraint necessitates a new approach to measuring
in vivo growth rates.
Utility of Highly Sensitive Stable Isotope Tracers for
Application in the Human Host
Stable isotope tracers (e.g., 13C, 2H, and 15N) have been used by
geobiologists to study the growth and metabolism of slowly growing
microbial populations in poorly accessible and energy-limited
habitats at the seafloor (9, 10), and in the deep biosphere (11).
Unlike methods that count cells or particular biomolecules,
isotope tracer methods can reveal growth rates that reflect
population biosynthetic activity regardless of whether the pop-
ulation is expanding, at steady state, or declining. Isotopic en-
richments thus provide a measure of biosynthetic turnover that is
independent of total biomass (Fig. 1A), making their use well-
suited to studies of infected human specimens like CF sputum,
where the size of the population can vary due to interactions with
other pathogens and the host immune system. Here, we used
heavy water (2H2O) because of its advantages as a chemically
and nutritionally passive isotope tracer when used at subtoxic
concentrations, and measured 2H incorporation into microbial-
specific fatty acids by gas chromatography/pyrolysis/isotope ratio
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mass spectrometry (GC/P/IRMS). Other 2H-based measures of
microbial activity have been used successfully in laboratory cultures
and animal models (12–14) but require high 2H incorporation
from heavy water (detection limits 2–3 atom% 2H). GC/P/IRMS,
however, can quantify isotopic enrichments well below 0.01
atom% 2H [and under ideal conditions as low as ∼0.0001 atom%
2H (15)] enabling much shorter incubation times as illustrated in
Fig. 1B, making this approach particularly well-suited for appli-
cation in samples from the human host environment.
Our aim in this study was to develop a method to quantify
average and single-cell growth rates for pathogens in chronic
infections. For this purpose, we targeted measuring the growth
rate of Staphylococcus aureus in CF sputum as a proof of principle.
Although CF infections are polymicrobial and compositionally
diverse, some bacterial species are common (16). S. aureus is one
of the earliest and most prevalent bacteria detected in infants and
children with CF, and has garnered attention in the last decade
due to the rise of beta-lactam-resistant strains (methicillin-
resistant S. aureus, or MRSA) (17). We therefore sought to measure
the growth rate of S. aureus within freshly expectorated CF sputum
both at the population and single-cell level. This approach has the
potential to be extended to quantify slow growth rates of diverse
organisms in many contexts, ranging from infectious diseases to
industrial fermentations to the deep subsurface.
Approach: Methods, Calculations, and Controls
To confidently estimate the in vivo growth rate using an isotope
labeling method, a number of factors must be taken into consid-
eration. These include identification of an appropriate biological
target molecule, controls to confirm biological compatibility of the
isotope label, access of the label to the sample, determination of
the extent of label incorporation into the target molecule during
biosynthesis, and estimation of how much anabolic activity can be
attributed to growth vs. maintenance. Fig. 2 presents an overview
of all aspects of our approach and highlights the relevant figures
for each step.
Identifying an appropriate biological target for analysis is of
primary importance, and several biological considerations must be
kept in mind (Fig. 2, marked in green). S. aureus synthesizes
specific fatty acids (the anteiso methyl branched C14 and C16
saturated fatty acids, hereafter referred to by their total carbon
numbers as a-C15:0 and a-C17:0, respectively) that can be dis-
tinguished from the human host and most other dominant CF
pathogens (Fig. S1), and which are synthesized de novo without
recycling (Fig. S2). The lack of fatty acid recycling by S. aureus
is a critical aspect for our quantitative approach: If organisms
build the targeted lipids from exogenous fatty acids, the amount
of 2H incorporated from heavy water would be greatly reduced
and therefore underestimate population growth rates. By targeting
specifically a-C15:0 and a-C17:0 for isotopic analysis, we could focus
on a suitable marker for S. aureus. Because heavy water can be
toxic at high concentrations (18), we further tested the suscepti-
bility of S. aureus to 2H2O to constrain its tolerance and found no
adverse effects at doses as high as 35% 2H2O (Fig. S3).
For the isotope labeling of clinical samples (Fig. 2, marked in
gray), CF sputum collected at Children’s Hospital Los Angeles
(CHLA) was suspended in a prewarmed PBS isotope labeling
solution (with 1% to maximally 30% vol/vol 2H2O to stay below
the susceptibility of S. aureus to 2H2O toxicity) within 5–10 min of
A
B
Fig. 1. Using stable isotope tracers to measure microbial activity. (A) Model
of a microbial population illustrates the change in biomass and the corre-
sponding isotope label incorporation over time after addition of an isotopic
spike. In all three scenarios, the isotopic enrichment proceeds identically,
allowing determination of the underlying growth rate from isotopic mea-
surements, regardless of total biomass accumulation or decline. (B) The
minimum incubation times required to detect microbial activity at analytical
detection limits of 0.01, 0.1, or 1 atom% 2H above natural abundance for
different average generation times of microbial populations exposed to a
10% 2H2O labeling solution. See Supporting Information for equations.
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Fig. 2. Schematic illustrating the experimental approach with clinical sample
acquisition, biological considerations, and data processing steps. Four stages
of the process are highlighted in color: sample labeling at the hospital (gray),
incorporation of the isotope label by the cells (green), measurement of spe-
cific fatty acids (guava), and quantitative data processing (gold). Specific bi-
ological considerations and data reduction steps are listed and point to the
relevant figures in the text and Supporting Information. In parentheses in
blue, we provide what the relative overestimates (+)/underestimates (-) of the
growth rates would be for the average clinical sample without the respective
corrections. For the uncertainty assessment of all parameters involved in the
growth rate calculations, please see Fig. S7. Also noted are the analytical
difference and data processing steps required for single-cell measurements.
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expectoration, and incubated at 37 °C for up to 60 min for bulk
growth rate measurements, and up to 2 h for single-cell analyses.
These relatively short incubation times were selected to preserve
the in situ sputum environment (19) as closely as possible during
the tracer incubation, while still ensuring long enough exposure
to the isotope label to allow for measurable incorporation into
slow-growing populations.
The resulting isotopic enrichment from growth of S. aureus in
the presence of the 2H-spiked water was then used to model the
apparent growth rate of the pathogen, taking into consideration
several potentially confounding factors (Fig. 2, marked in gold).
The first concerns the noninstantaneous penetration of the iso-
tope label into a clinical sample. On the time scale of long en-
vironmental incubations lasting days or months, the time it takes
for heavy water to mix into the sample would be negligible, but,
due to the short incubation time (∼1 h), this effect becomes
relevant, and we parametrized the mixing rate empirically by
using isotope label equilibration times in clinical samples (Fig.
S4). The second concerns the hydrogen metabolism of S. aureus
during fatty acid biosynthesis. Although newly synthesized fatty
acids follow the isotopic composition of water, this is generally
not a 1:1 relationship, because of enzymatic kinetic isotope
effects during biosynthesis and because not all H atoms are
derived from water during heterotrophic growth. The appro-
priate value for the resulting water hydrogen assimilation by
S. aureus growing in clinical samples was determined experi-
mentally in synthetic CF sputum medium (SCFM) (20) following
previously established methods (21) (Fig. S5). Finally, because
our approach captures the overall anabolic activity, including both
the specific growth rate (which signifies true cellular replication)
and the maintenance turnover rate (which describes biosynthesis
in excess of growth to compensate for degradation and material
turnover), quantifying growth requires constraints on the mainte-
nance contribution. We thus grew S. aureus in chemostat culture
at a controlled, slow growth rate of 0.14 divisions per day
(doubling time of 4.9 d) in SCFM, and measured 2H incorpo-
ration after a 2H2O spike to approximate the contribution of
maintenance turnover to fatty acid 2H uptake (Fig. S6).
Using these constraints, we could infer the apparent growth
rate of S. aureus in clinical samples by numerically fitting the
clinical data (2Ffa and
2Fw, the fractional isotope abundances of
2
H measured in fatty acids and sputum water, respectively) to the
following equation (full derivation in Supporting Information):
2FfaðtÞ= aw ·

2Fweq − 2Fwnat

·

1− e−ðμ+ωÞ · t−
μ+ω
μ+ω+ k
·

1− e−ðμ+ω+kÞ·t

+Ffaoriginal .
[1]
This takes into consideration the aforementioned incorporation
of hydrogen from water by S. aureus (aω), rate of label exchange
with the mucus (k), and turnover rate (ω). Uncertainties associ-
ated with these parameters are discussed in Supporting Informa-
tion (Fig. S7). It is important to note that if the chemical
environment within the sputum requires even higher relative
rates of fatty acid maintenance/repair than the chemically stable
environment of the chemostat, the clinical growth rates would be
even lower than currently estimated.
Results and Discussion
Growth Rates of S. aureus Populations in Clinical Samples. Having
performed these control experiments, we set out to collect a
robust cross-sectional dataset from CF patients. Fig. 3 displays
the average growth rate of S. aureus populations in 37 samples
from 16 patients. The growth rate range for each sample is
constrained by the a-C15:0 and a-C17:0 S. aureus specific fatty
acid isotope enrichments, and the average rates are calculated
from their mass balance. Major potential contributions to these
specific fatty acids by other organisms (e.g., Stenotrophomonas
maltophilia, Fig. S1) were ruled out on the basis of 16S rRNA
gene sequencing, which indicated that Staphylococcaceae were
far more abundant (54% on average, Table S1) than the entire
family of Xanthomonadaceae to which Stenotrophomonas be-
longs (0.4%). Although the calculated in vivo growth rates of S.
aureus vary between patients and even between samples from a
single patient, all values are 2–100 times lower than the rates at
which this organism is typically grown in the laboratory (22).
The slow average growth rates suggest that S. aureus populations
experience environmental constraints within the lung environ-
ment. Unlike in many aquatic environments in nature, carbon and
nitrogen limitations are less likely to occur within the organic-rich
CF sputum environment where millimolar concentrations of free
amino acids and other potential nutrient sources have been
measured (20). Research into the in situ concentrations and limits
of oxygen penetration in sputum points to oxygen availability as a
likely dominant growth constraint (19, 23), in addition to in-
hibition by microbial competitors in the polymicrobial environ-
ment (24), as well as effects from continuous antibiotic treatment
in these patients and the activity of the immune system (6). Future
work in a more expansive longitudinal study of sputum samples
artificially amended with different nutrients and antibiotics will
help shed light on the factors restricting pathogen growth.
Fig. 3. Average growth rates of S. aureus in CF sputum are slow. S. aureus
population growth rates calculated from the isotopic enrichment of S. aureus
specific membrane components (a-C15:0△, a-C17:0,∇) and the abundance-
weighted average isotopic composition for each data point (○/□). Growth rates
are plotted on a logarithmic scale. Symbol size illustrates the relative abundance
of the component within each sample. Error bars indicate the propagated error
estimate on the population growth rate (Fig. S7). Dashed vertical lines connect
the a-C15:0 and a-C17:0 data points of each sample. Samples are grouped by
patient health status (well vs. sick) and color-coded by patient. Samples from
sick patients are sorted in ascending order by their hospital stay day. Samples
from patients whose treatment regimen at the time included any antibiotics
active against S. aureus are marked with □ instead of ○. (Antibiotics are
vancomycin, oxacillin, piperacillin/tazobactam, amoxicillin/clavulanic acid, tri-
methoprim/sulfamethoxazole, cefazolin, clindamycin, ciprofloxacin, tetracycline,
linezolid, unless S. aureus resistance to the antibiotic was reported for the sample;
see Table S1 for details.) Separate column (chemostat) shows a representative
growth rate from a chemostat culture of S. aureus (Fig. S6), demonstrating that it is
possible to model slow clinically relevant growth rates in the laboratory. Area
highlighted in blue represents the typical range of growth rates studied in labo-
ratory experiments with S. aureus.
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The data in Fig. 3 also reveal a systematically higher 2H en-
richment of a-C15:0 over a-C17:0 fatty acids that is more pro-
nounced than the equivalent pattern observed for S. aureus
grown in chemostat culture in SCFM. Interestingly, S. aureus
appears to shift its membrane fatty acid composition in response
to slower growth (Fig. S8), a phenomenon also observed in other
microorganisms (e.g., refs. 25 and 26). This could explain the
systematically higher 2H enrichment of a-C15:0 if substantial
heterogeneity exists in the underlying staphylococcal population,
with slower-growing cells preferentially producing a-C17:0 and
faster-growing cells producing more a-C15:0.
Heterogeneity of Microbial Activity. To test the hypothesis that
substantial population heterogeneity exists, we used FISH coupled
to secondary ion mass spectrometry (FISH-NanoSIMS) to measure
isotope incorporation at the single-cell level (27). Growth rates
from single-cell 2H enrichments were calculated by converting thin-
section NanoSIMS measurements to corresponding bulk mem-
brane enrichments (details in Supporting Information). Fig. 4A
shows representative FISH-NanoSIMS images for two cell clusters,
illustrating the potential for significantly different in vivo single-cell
growth activities on a small scale. The cluster on the left did not
incorporate 2H above background, indicating that the cells were
dormant or dead, whereas the cluster on the right incorporated a
large amount of 2H within the 2-h incubation. In this visual field,
clusters are microbial (identified by the bacterial FISH probe
EUB338), but neither contains S. aureus cells.
For the quantitative NanoSIMS analysis shown in Fig. 4B,
however, we targeted cells that hybridized specifically with an
S. aureus FISH probe (28). The abundance of Staphylococcaceae
in the patients whose sputum was analyzed by NanoSIMS ranged
from 42 to 56% (Table S1). The smoothed density distribution of
the aggregated single-cell growth rates is illustrated for all mea-
sured S. aureus cells per patient sample. We observed substantial
growth rate heterogeneity in all measured samples, with a partic-
ularly wide, apparently bimodal distribution observed in the third
sample. Sample 4 also contained a large number of unidentified
bacteria that were neither S. aureus nor P. aeruginosa, and appear
to be consistently more active than the cooccurring S. aureus
population (potential candidates from 16S data include members
of the Moraxellaceae and Erythrobacteraceae, with sequence abun-
dances of 13% and 9%, respectively). That S. aureus and other
bacteria exhibit heterogeneous metabolic activity in vivo is con-
sistent with a growing body of literature documenting the impor-
tance of heterogeneity in a wide range of systems (29–31).
Moreover, this heterogeneity may help explain why antibiotic
treatments are not fully effective: If a reservoir of slowly growing
cells exists for any bacterial species being targeted by antibiotics
whose efficacy requires fast growth rates, it is not surprising that
25% of pulmonary exacerbations fail to recover to baseline health
after treatment with i.v. antibiotics (32).
Correlation with Clinical Parameters.Despite this heterogeneity, we
asked whether the average growth rate of S. aureus in CF sputum
correlates with particular host characteristics and clinical met-
rics. There were no significant relationships between S. aureus
growth rates and host age, sex, body mass index (BMI), or lung
function (as measured by forced expiratory volume FEV1%) nor
with the community abundance of Staphylococcaceae or presence
of the pathogen P. aeruginosa (Table 1). Unexpectedly, S. aureus
activity showed a statistically significant positive correlation with
the day of the patient’s hospital stay (i.e., higher apparent growth
rates the longer a patient had been in the hospital) with a
transient decrease in growth rates early on. Additionally,
S. aureus populations show significantly higher growth rates in
samples from patients who were well (pulmonary function at
baseline) compared with samples from patients who were acutely
sick (suffering a pulmonary exacerbation; Fig. 3 and Fig. S9).
Intriguingly, on average, S. aureus growth rates were signifi-
cantly lower when patients were taking the antibiotics vanco-
mycin, piperacillin/tazobactam, or tobramycin at the time of
sampling compared with when patients were not taking the re-
spective antibiotic (Table 1 and Fig. S10), but no statistically
significant trends were observed for the antibiotics aztreonam,
colistin, and moxifloxacin. Although tobramycin is primarily used
against P. aeruginosa, both piperacillin/tazobactam and vanco-
mycin have antistaphylococcal activity. We also note, however,
that we were unable to determine whether these correlations held
statistical significance for individuals, due to the limited number
of patient-specific longitudinal samples (Fig. S10). Generally, at
the individual level, being on any antistaphylococcal antibiotics at
the time of sampling exhibited no clear trend with respect to
growth rate (Fig. 3). Intriguingly, the growth rate of S. aureus in
some patients at the beginning of their hospital stay appeared to
slow, with a return to baseline well before discontinuation of the
treatment (e.g., red and teal, Fig. 3). Such dynamics make it
tempting to speculate that early during a hospital stay, treatment
with anti-Staph antibiotics depresses S. aureus growth rates, yet,
because patients are simultaneously given many drugs that target
various members of microbial community, as other bacteria are
eradicated over time, S. aureus experiences resource expansion
and/or reduced antagonism and begins to grow more quickly. We
emphasize, however, that this speculative interpretation requires
testing in dedicated longitudinal studies where multivariable re-
gression models can help parse out the interplay between health
indicators, treatment regimen, and pathogen growth rate.
Conclusions. Our studies of S. aureus in CF sputum reveal that
pathogen growth rates can be far slower and more heterogeneous
in human infections than previously assumed. Nevertheless, the
A B
Fig. 4. NanoSIMS analysis reveals that single-cell growth rates are diverse. (A)
(Top) Example of target identification and 2H enrichment in plastic sections.
Frames shown are 10 × 10 μm, (Bottom) First column shows microscopy pictures
with overlaid DAPI (blue), bacterial EUB338 FISH (red), and sample auto-
fluorescence in the GFP channel (green); second column shows autofluorescence
alone (contrast enhanced for mapping to ion image); third column shows
the 14N12C− ion image; fourth column shows the fractional abundance image
of 2H. (Scale bar in ion maps, 1 μm.) (B) Distribution of single-cell growth
rates of S. aureus cells (in red) in four clinical samples using the approach
described in Supporting Information. An unidentified group of bacteria (in
blue) was captured in the fourth sample. Bars indicate the measured growth
rates of individual cells. Curves illustrate smoothed density distribution
function of the data. Growth rates plotted on logarithmic scale.
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range of growth rates that we observe here is largely accessible to
experimental replication within laboratory models. Understanding
metabolic diversity during slow growth, and how this impacts
survival strategies for microorganisms, is a poorly developed but
fundamental aspect of microbial physiology and ecology in any
environment. What strategies do cells take to control core pro-
cesses such as transcription, translation, and membrane integrity
when persisting in a slow growth mode? How different are these
strategies from those that promote cellular homeostasis when
nutrients are plentiful and growth is fast? The answers to these
and other questions in the context of pathogen behavior in chronic
infections are important to understand for practical reasons. For
example, Mycobacterium tuberculosis is known to persist under
hypoxic, nonreplicating conditions (33); encouragingly, inhibition
of membrane components that contribute to electron transport
and/or proton translocation under these conditions shows prom-
ise for shortening the time of tuberculosis therapy (34, 35). Ul-
timately, a better understanding of how populations grow in vivo
is crucial to developing representative in vitro tests of potential
therapies for diverse pathogens that infect the human host (36).
Materials and Methods
Study Design. All patients were recruited from CHLA and gave informed
consent or assent in accordancewith IRB CCI-13000211. Inclusion criteria were
a positive diagnosis of CF, ability to expectorate sputum, and recent detection
of an infection by S. aureus from clinical data.
Sample Collection. Immediately upon expectoration (within 5–10 min), spu-
tum samples were suspended at the hospital in a prewarmed PBS isotope
labeling solution (with 1–30% vol/vol 2H2O), and incubated at 37 °C for up to
60 min. Microbial growth activity in samples for lipid analysis was arrested by
flash-freezing in liquid nitrogen at the end of sample incubation, and sam-
ples were preserved at −80 °C. Typically, most pediatric patients could not
expectorate more than 0.5–1 g of sputum, but when sufficiently large spu-
tum samples (>0.6 g) were expectorated, the sample was divided before
isotope labeling with a scalpel or by transfer with a large syringe. Samples
for single-cell analysis were treated the same as bulk samples, except for
extension of incubation times up to 2 h (with 10–15% 2H2O), and arrest of
microbial activity at the end of incubation by transfer to a freshly thawed 1%
formaldehyde solution in PBS. Just before sample preservation, the residual
labeling solution was collected and filter-sterilized for water isotope analysis.
Isotope Notation. Isotopic measurements were recorded in the conventional
δ-notation (δD= δ2H= ½ð2Rsample − 2Rref Þ=2Rref ) relative to the international
reference VSMOW [2RVSMOW = 2H=1H= 0.00015576(37)]. To allow consistent
reporting and exact mass balance calculations, all measurements were con-
verted to fractional abundances F (2F = ½2H=ð1H+ 2HÞ) using the relation
xFsample = ½xRsample=ð1+ xRsampleÞ= ½ðδx +1Þ=ð1=xRref + δx + 1Þ and are reported
in atom percent (atom%). Data quantification and evaluation of analytical
uncertainties are discussed in more detail in Supporting Information.
Water Isotope Analysis. The water hydrogen isotopic composition (2Fw) of all
samples was measured using a Los Gatos Research DLT-100 liquid water iso-
tope analyzer. Samples were analyzed in at least three replicate analyses with
10 injections each. Samples close to natural abundance isotopic composition
were calibrated against four working standards (δ2H values: −117‰, −11‰,
+290‰, +1,270‰) that in turn were calibrated against the VSMOW, GISP, and
SLAP international standards (38). Heavily enriched samples from isotope
tracer solutions were beyond the linear response range of the instrument and
were analyzed by dilution with water of known isotopic composition.
Fatty Acid Analysis. Frozen sputum samples were lyophilized for at least 48 h.
Homogenized dry powder was weighed into ∼40-mg aliquots (or the maxi-
mum available amount), and spiked with 10 μg 21:0 phosphatidyl choline as a
phospholipid extraction standard. Samples were transesterified in the pres-
ence of a base catalyst (0.5M NaOH in anhydrous methanol) at room tem-
perature for 10 min (39). Free fatty acids and aldehydes are not esterified
under basic conditions, which prevents the derivatization of fatty acids from
degraded materials in the sputum sample, as well as the derivatization of
abundant aldehydes, which interfere chromatographically with target analy-
tes. Derivatized fatty acid methyl esters (FAMEs) were extracted into hexane,
and concentrated under a stream of N2 at room temperature. Because primary
target analytes (a-C15:0 FA and a-C17:0 FA) typically constituted less than 1% of
host-derived fatty acids, the high abundance of host material [primarily C18:1
FA, C18:2 FA, and longer chain (poly)-unsaturated fatty acids] interfered with
compound-specific isotope ratio analysis of these compounds due to column
overload. The low total amount of target analytes available from most sample
sizes precluded the use of elaborate purification steps with low yields or risk of
contamination. To remove several major host compounds and increase relative
abundance of the analytes sufficiently for isotope ratio analysis, saturated
Table 1. S. aureus growth rates vs. health and treatment indicators
Clinical parameter Samples Data range Statistic† P value Significance
Age 37 9–20 y of age Spearman (−0.23) 0.2 —
Sex 37 female (8), male (29) MWW (female > male) 0.3 —
Race 37 Hispanic (21), Non-Hispanic White (11), African-American (5) Spearman (−0.23) 0.2 —
BMI 33 14.1–21.3 kg/m2 Spearman (0.18) 0.3 —
FEV1% 37 20–118% predicted Spearman (0.06) 0.7 —
Pulmonary exacerbation 37 no (20), yes (17) MWW (no > yes) 0.004 **
Hospital day 15 day 1–30 Spearman (0.53) 0.04 *
P. aeruginosa present‡ 32 no (21), yes (11) MWW (no > yes) 0.1 —
Staphylococcacea‡ 32 40–71% Spearman (−0.12) 0.5 —
Vancomycin§ 37 treatment at the time included this antibiotic: no (32), yes (5) MWW (no > yes) 0.002 **
Piperacillin/tazobactam§ 37 treatment at the time included this antibiotic: no (30), yes (7) MWW (no > yes) 0.003 **
Tobramycin§ 36 treatment at the time included this antibiotic: no (11), yes (25) MWW (no > yes) 0.05 *
Inhaled aztreonam§ 36 treatment at the time included this antibiotic: no (27), yes (9) MWW (no > yes) 0.1 —
Colistin§ 36 treatment at the time included this antibiotic: no (27), yes (9) MWW (no > yes) 0.1 —
Moxifloxacin§ 36 treatment at the time included this antibiotic: no (31), yes (5) MWW (no > yes) 0.3 —
Summary of statistical relationships between S. aureus average population growth rate and different health and treatment indicators by Mann−Whitney
−Wilcoxon (MWW) test (for binary parameters) or Spearman rank analysis. Spearman’s P < 0 indicates positive correlation (i.e., faster growth rate with increase of
the clinical parameter), and P < 0 indicates a negative correlation. See Table S1 for all data, and see Figs. S7 and S8 for correlation plots. Only antibiotics with at
least five samples in each category (yes/no) were analyzed. —P > 0.05, *P ≤ 0.05, **P ≤ 0.01.
†Evaluated by MWW test for binary parameters (sex, pulmonary exacerbation, and P. aeruginosa presence; each was evaluated for both alternative
hypotheses; the most statistically significant alternative is given) and by Spearman rank analysis for all other parameters.
‡The presence of P. aeruginosa was tested in routine clinical selective plating screens. The abundance of Staphylococcaceae was assessed by 16S rRNA gene
sequencing.
§Vancomycin is used against Gram-positive pathogens including MRSA; piperacillin/tazobactam is used against P. aeruginosa and some S. aureus (not effective
against MRSA); tobramycin, aztreonam, and colistin are mostly used against P. aeruginosa; moxifloxacin is a broad-spectrum antibiotic mostly used against
mycobacteria.
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FAMEs were separated from unsaturated FAMEs using Discovery Ag-Ion solid-
phase extraction columns in combusted glass cartridges (Supelco; custom
preparation to avoid contaminants from plastic columns). Extracted sam-
ples were dried to 1 mL and applied to preconditioned columns, followed
by elution of saturated FAMEs in 0.125% acetone in hexane, and mono-
saturated and disaturated FAMEs in acetone. Separation of unsaturated
and saturated fatty acids was quantitative using this procedure. Fractions
were evaporated to dryness and resuspended in hexane before analysis.
FAMEs were analyzed by gas chromatography/mass spectrometry (GC/MS)
on a Thermo-Scientific Trace DSQ equipped with a ZB-5ms column (30 m ×
0.25 mm i.d., film thickness 0.25 μm) and PTV injector operated in splitless
mode, using He as a carrier gas at 0.8 mL/min. The GC oven was held at 80 °C
for 1 min, ramped at 20 °C/min to 130 °C, and ramped at 5 °C/min to a final
temperature of 320 °C (held for 20 min). Peaks were identified by compar-
ison of mass spectra and retention times to authentic standards and library
data. Fatty acids are referred to using the nomenclature z-Cx:y, where x is the
total number of carbons in the fatty acid skeleton (regardless of structure),
y is the number of double bonds, and z- is a prefix describing additional
structural features of the compound. The position and stereochemistry of
the double bonds or cyclopropyl rings was not determined. The isotopic
composition of the primary target analytes was measured in the saturated
FAME fraction by GC/pyrolysis/isotope-ratio mass spectrometry on a Thermo-
Scientific Delta+XP with methane of known isotopic composition as the
calibration standard. A multicompound FAME standard was run every four
to six samples to verify instrument accuracy and precision. Chromatographic
conditions were identical to those from GC/MS analysis except for a thick-
film column (ZB-5ms, 30 m × 0.25 mm i.d., film thickness 1.00 μm) and slight
modifications to the temperature program to optimize chromatographic
separation of i-C15:0 and a-C15:0/i-C17:0 and a-C17:0 despite peak broadening
from isotope labeling and heavy column loading. Samples were injected in
highly concentrated aliquots to obtain maximum signal for target analytes.
Peaks were identified based on retention order and relative height based on
the GC/MS analysis. High-abundance components in the saturate fraction
(C16:0, C18:0, C20:0) that were too concentrated relative to target analytes
were prevented from entering the source by appropriately timed backflush
of the column effluent. Relative proportions of fatty acids for isotope mass
balance calculations were determined from peak areas corrected for de-
rivatization and isotopic composition.
Single-Cell Analysis. Immediately upon receipt of samples from the hospital,
formaldehyde-fixed sputum samples were transferred to excess PBS solution
(10 mL) in a column above an 8-μm sterile filer. The sample was washed by
slowly rinsing it with a total of 50 mL PBS solution that was added to the
column in 10-mL aliquots and drained by gravimetric or slight vacuum flow
through the filter. Samples were suspended in drops of molten noble agar
[2% (wt/vol) Difco Agar Noble in 50 mM Hepes buffered filter-sterilized water],
solidified by cooling at room temperature, and cut into ∼2-mm3 cubes. Fixed
and washed agar cubes were incubated for at least 1 h at 30 °C in freshly
prepared 1mg/mL lysozyme and 50 μg/mL lysostaphin (L2898; Sigma-Aldrich)
in 10 mM Tris buffered water to digest S. aureus cell wall, washed once in
PBS, resuspended in 50% (vol/vol) ethanol in PBS, and dehydrated in 100%
ethanol over the course of three exchanges, with final resuspension in 100% for
at least 1 h. Ethanol was then replaced twice with 100% Technovit 8100
infiltration solution (64709012; Heraeus Kulzer GmbH) to infiltrate the agar
cubes overnight. Agar cubes were finally suspended in airtight 0.6-mL
microcentrifuge tubes in Technovit 8100 infiltration solution amended with
hardener II reagent and stored at 4 °C for overnight polymerization. Thin
sections (1 μm thick) were cut using a rotary microtome. Each section was
stretched on the surface of a water drop on polylysine-coated microscope
slides and air-dried at room temperature.
FISHwas conducted on the plastic thin sections using the universal bacterial
probe EUB338 [5′ to 3′: GCT GCC TCC CGT AGG AGT (40)], which hybridizes to
bacterial 16S rRNA, probe Sau [5′ to 3′: GAA GCA AGC TTC TCG TCC G (28)],
which hybridizes to S. aureus 16S rRNA, and probe Psae [5′ to 3′: TCT CGG
CCT TGA AAC CCC (41)], which hybridizes to P. aeruginosa 23S rRNA. Both
probes were specifically designed and tested for use in microbial identifica-
tion in CF sputum (41, 42). Additionally, probe Non338 [5′ to 3′: ACT CCT ACG
GGA GGC AGC (43)], an oligonucleotide complementary to the probe EUB338,
served as a negative control for nonspecific binding. Probes EUB338 and
Non338 were labeled with the cyanine dye Cy3, probe Sau were labeled
with the cyanine dye Cy5, and probe Psae were labeled with fluorescein.
All probes were labeled on both the 5′ and 3′ end to increase fluorescence
intensity (44). For hybridization, each section was covered with 20 μl of hy-
bridization buffer [0.9 M NaCl, 20mM Tris·HCl at pH 8, 0.01% SDS, 20% (vol/vol)
formamide (28, 42)] containing 50 ng of unlabeled oligonucleotide probe
BET42a [5′ to 3′: GCC TTC CCA CTT CGT TT (45)] and preincubated for 10 min
at 46 °C to reduce nonspecific binding of labeled oligonucleotide probes
(41). Probes EUB338 (or Non338), Sau, and Psae were added (5 ng/μL), and
samples were incubated in a moisture chamber at 46 °C for 3 h. Stringent
washing was performed by incubating the samples in washing buffer at
decreased NaCl concentration [225 mM NaCl with 5 mM EDTA, 20 mM
Tris·HCl at pH 8, 0.01% SDS (46)] at 48 °C for 12 min. Finally, samples were
dipped into ice-cold deionized water to rinse off the salt, air-dried, and
mounted in the glycerol-based soft mount Vectashield (Vector Laboratories)
(47) with 1.5 μg/mL 4′,6-diamidino-2-phenylindole (DAPI) as a DNA coun-
terstain. Samples were routinely imaged using a Zeiss Axio Imager micro-
scope, and mapped extensively for sample identification and target localization
for FISH−NanoSIMS using a Keyence BZ-9000 microscope equipped with a
mercury lamp and filter cubes for DAPI, GFP, Cy3, and Cy5. For secondary ion
mass spectrometry, samples were made conductive by sputter-coating with
a 50-nm layer of gold.
All samples were analyzed with a CAMECA NanoSIMS 50L (CAMECA)
housed in the Division of Geological and Planetary Sciences at California
Institute of Technology. Cells in plastic thin sectionswere analyzed using a 1.9-
to 3.6-pA primary Cs+ beam, and were presputtered with a ∼ 200-pA primary
Cs+ beam current (Ipre) for 3–15 min (t), depending on the size of the pre-
sputtering area (A), to a cumulative charge density of ∼ 30 pC/μm2 (Ipre · t=A).
Seven masses were collected in parallel (1H−, 2H−, 12C−, 13C−, 14N12C−, 15N12C−,
and 28Si−) using the configuration reported in ref. 27. Target locations in
individual samples were located using the NanoSIMS CCD camera, secondary
electron image, and 14N12C− ion maps. For all analyses, the beam was ras-
tered over a square region ranging from 5 × 5 μm2 to 50 × 50 μm2 for
5–30 min per analytical plane/frame, and images were collected in 256 × 256
pixel resolution up to 12 × 12 μm2 and 512 × 512 pixel resolution for larger
areas. Presputtering was carried out on a region larger than the analytical
frame by at least 2 μm on each side. Analytical parameters including primary
beam focus, secondary beam centering, and mass resolution for all ions were
verified every ∼30 min. To correct for instrument mass fractionation and
matrix effects of the plastic polymer, we calibrated plastic-embedded single-
cell measurements against bacterial isotope standards that were analyzed at
the same time and were previously presented in detail (27). Data evaluation
is discussed in more detail in Supporting Information.
The 16S Ribosomal RNA Gene Sequencing. DNA was prepared from ∼1 mg
lyophilized sputum samples treated with 2% vol/vol PBS/β-mercapto-ethanol
for 2 h at room temperature and Sputolysin (Calbiochem) for 30 min at
37 °C, followed by lysis in 180 μL of buffer ATL (Qiagen Blood and Tissue
DNeasy kit) amended with lysostaphin (final concentration 0.14 mg/mL) and
lysozyme (final concentration of 2.9 mg/mL) (48) for 2 h at 37 °C, bead-
beating with 0.1-mm glass beads for 10 min, and extraction using the Qia-
gen Animal Tissues Spin Column Protocol with 20 μL proteinase K during
overnight incubation. High throughput sequencing was performed as pre-
viously described (49). Briefly, purified DNA was amplified in triplicate using
16S rRNA Illumina barcoded primers specific to the V4 region of the 16S
rRNA gene. Samples were pooled, and paired-end sequencing was per-
formed on an Illumina MiSeq platform at CHLA. Sequences were demulti-
plexed and trimmed, and paired-end reads were joined, trimmed according
to quality score, and checked for chimeras. Sequences were assigned to de
novo OTUs (operational taxonomic units) using uclust (50) to search sequences
against the Greengenes database (2014 version), and were assigned if the
sequence matched the database at 97% similarity or greater. If a read did not
match a database sequence, it was considered unassigned. Taxonomy was
assigned at the family level based on the Greengenes matching sequence. The
genera Geobacillus, Rhodothermus, and Rhodocyclaceae were considered to
be contaminants and were filtered out from the results. Table S1 includes the
sequence abundances of the S. aureus family Staphylococcaceae, and the
S. maltophilia family Xanthomonadaceae (the main organism with partly
overlapping fatty acid profiles).
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